TTrialPathMatch Me to Trials
← Back to trials
RecruitingNon-Alcoholic Fatty Liver DiseaseType 2 DiabetesMitochondrial Metabolism Disorders

Quantifying Hepatic Mitochondrial Fluxes in Humans

Eligible age

18–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

Sponsor: The University of Texas Health Science Center at San Antonio

You may qualify if…

  • ✓ Confirmed T2D based on OGTT (2 h glucose ≥200 mg/dl).
  • ✓ Treated with diet, metformin, and/or sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries;
  • ✓ age = 18-80 years;
  • ✓ BMI = 25-40 kg/m2;
  • ✓ HbA1c = 7-10%; stable body weight (±4 pounds) over the preceding 3-months;
  • ✓ not taking any medication known to affect glucose metabolism other than antidiabetic medications.
  • ✓ Evidence of moderate/severe fatty liver (steatosis; grade S2/S3 on FibroScan corresponding to ≥10% fat on MRI-PDFF) and no/minimal hepatic fibrosis (grade F0/F1 on FibroScan).
  • ✓ Confirmed T2D based on OGTT (2 h glucose ≥200 mg/dl).

You may not qualify if…

  • ✕ Alcohol consumption \>14 units/week for women and \>21 units/week for men.
  • ✕ Liver cirrhosis (fibrosis stage 4).
  • ✕ Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected/proven liver cancer and any other liver disease other than NAFLD.
  • ✕ Type 1 diabetes and/or GAD positive subjects.
  • ✕ Subjects not drug naive or have been on metformin more than 3 months.
  • ✕ Presence of proliferative retinopathy.
  • ✕ Urine albumin excretion \> 300 mg/day.
  • ✕ History of NY Class III-IV heart failure

Where it's recruiting

Texas

San Antonio

Source: ClinicalTrials.gov · NCT05305287 · last updated 2026-08-17

Quantifying Hepatic Mitochondrial Fluxes in Humans · TrialPath